Puridify, a UK-based developer of a nanofiber-based platform purification technology for the biopharmaceutical industry backed by pharmaceutical firm GlaxoSmithKline, was acquired by healthcare company GE Healthcare yesterday.
Financial terms of the transaction have not been disclosed.
Puridify has developed technology, dubbed FibroSelect, that improves the efficiency of purification in biopharmaceutical production. The technology is based on research at University College London (UCL)’s Department of Biochemical Engineering.
Following the acquisition, GE Healthcare will invest in Puridify to commercialise the technology and…
